Codexis launches stock offering, backs $72M–$76M 2026 revenue outlook
What's the deal? Codexis (CDXS:NASDAQ) said in July 2026 it launched an underwritten public offering of its common stock. The enzyme engineering company plans to grant underwriters a 30-day option to buy up to an additional 15% of the shares offered.
What's the money for? Codexis plans to use the proceeds for working capital and general corporate purposes, including research, development, and business activities.
The numbers: The offering follows a first quarter in which Codexis posted revenue of $15.2 million, beating estimates by $0.67 million. GAAP loss per share came in at $0.10, $0.04 better than expected.
What's the endgame? The company has reiterated its 2026 revenue outlook of $72 million to $76 million. It is targeting 0.5 kilogram ECO Synthesis scale by year-end.
The signal: Tapping public markets for a post-IPO equity raise gives Codexis a cash cushion to fund its research push as it works to scale its synthesis platform, without adding debt.
Read more: Seeking Alpha
Image credit: U.S. Department of Energy
